CEO and Chairman of the Board · SOLENO THERAPEUTICS INC (SLNO)

Anish Bhatnagar

A named executive officer of SOLENO THERAPEUTICS in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$8,872,611

Salary $739,000Stock awards $2,650,263

FY2024: $51,160,430

1st of 5 named executive officers at Soleno Therapeutics by FY2025 total.

5 named officers on file for SOLENO THERAPEUTICS, FY2025

Anish Bhatnagar’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • SLNO’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SOLENO THERAPEUTICS’s whole pay program stands against its peers

  • SOLENO THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SLNO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (10-K/A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Anish Bhatnagar’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anish Bhatnagar compensation by year

SOLENO THERAPEUTICS Summary Compensation Table · all 3 fiscal years held
In US dollars, as SOLENO THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$556,800$640,000$739,000
Bonus$0$0$0
Stock awards$843,161$46,883,000$2,650,263
Option awards$2,216,473$3,231,230$4,991,608
Non-equity incentive$500,000$403,200$487,740
Pension and deferred compensation$0$0$0
All other$0$3,000$4,000
Total$4,116,434$51,160,430$8,872,611

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SOLENO THERAPEUTICS INC 10-K/A filed April 30, 2026, accession 0001193125-26-197594, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SOLENO THERAPEUTICS INC filed document, accession 0001193125-26-197594. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$4.1M
$51.2M
$8.9M
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU40,425$1,871,678—
Option27,084—$36.70
Option89,109—$49.17
Option848—$5.10
Option66,918—$5.25
Option31,146—$2.41

Per the Outstanding Equity Awards at Fiscal Year-End table in SOLENO THERAPEUTICS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

12 Form 4 lines since the FY2025 proxy (filed April 30, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-18Disposition to the issuer—583,656—0
2026-05-18Disposition to the issuer derivative—22,452—0
2026-05-18Disposition to the issuer derivative—60—0
2026-05-18Disposition to the issuer derivative—23,332—0
2026-05-18Disposition to the issuer derivative—35,000—0
2026-05-18Disposition to the issuer derivative—8,473—0
2026-05-18Disposition to the issuer derivative—73,333—0
2026-05-18Disposition to the issuer derivative—52,709—0

The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

SOLENO THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Anish Bhatnagar · this pageCEO and Chairman of the Board$8,872,611
Manher JoshiChief Development Officer$3,721,576
Kevin NorrettChief Business Officer$3,369,336
James MackanessFormer Chief Financial Officer$2,786,453
Meredith ManningChief Commercial Officer$2,606,156

Board service

SOLENO THERAPEUTICS board · FY2024

How this board is paid

Company policy: SOLENO THERAPEUTICS pays directors a $42,500 cash retainer and $300,000 in RSUs. As stated in SOLENO THERAPEUTICS's FY2024 proxy.

The full SOLENO THERAPEUTICS compensation record

free company brief

This page is one person within SOLENO THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SOLENO THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anish Bhatnagar's compensation dossier · One-time report. No refunds.